Antiviral therapy can also alter T cell function, with CD8+ tumor-infiltrating lymphocytes expressing higher effector T cell markers and lower T cell exhaustion markers in patients receiving antiviral therapy, playing a adjuvant role in the anti-tumor effects of ICIs (63). This evidence concerns the gene CD8A and neoplasm.